ACTRN12610000481077.

Study name	The effectiveness of guideline‐driven antiemetic therapy versus single agent antiemetic therapy in patients with cancer and nausea not related to cancer therapy. A two‐stage trial of response to antiemetic therapy in patients with cancer and nausea not related to anticancer therapy. Study 1: a randomised open label study of guideline‐driven targeted antiemetic therapy versus single agent antiemetic therapy.
Methods	Randomised Controlled Trial Multi‐centre, open‐label randomised parallel arm trial. Participants are randomised to active treatment arms 1 or 2.
Participants	Patients with cancer and nausea not related to anticancer therapy.
Interventions	Arm 1: targeted guideline‐driven antiemetic therapy dependent on presumed cause of nausea. Arm 2: haloperidol in a three‐step dose escalation schedule from 1mg over 24 hours to 3mg over 24 hours given orally or parenterally (subcutaneously).
Outcomes	Primary outcome: response to treatment at 72 hours. Response defined as at least a two‐point improvement in average nausea score from baseline and final score less than 3 on an 11‐point numeric rating scale.
Starting date	First enrolment 15 June 2010.
Contact information	Professor Patsy Yates Head of School, Faculty of Health, School ‐ Nursing Queensland University of Technology, Brisbane QLD 4001 Australia
Notes	Preliminary results of this study were published as a conference abstract in 2014 (see Yates 2010 secondary reference).